AstraZeneca PLC (NYSE:AZN)

37.04
Delayed Data
As of May 25
 +0.16 / +0.43%
Today’s Change
28.43
Today|||52-Week Range
37.30
+6.74%
Year-to-Date
Is Syndax Pharmaceuticals Worth a Look After Its Recent Drop?
May 22 / GuruFocus News - Paid Partner Content
Royal Wedding Stirs Interest in U.K. Stocks
May 18 / Zacks.com - Paid Partner Content
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
May 22 / Zacks.com - Paid Partner Content
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
May 18 / Zacks.com - Paid Partner Content
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
May 21 / Zacks.com - Paid Partner Content
Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
May 17 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
May 18 / Zacks.com - Paid Partner Content
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
May 14 / Zacks.com - Paid Partner Content
Royal Wedding In Focus
May 18 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close36.88
Today’s open36.82
Day’s range36.74 - 37.15
Volume5,445,190
Average volume (3 months)4,308,054
Market cap$92.3B
Data as of 4:03pm ET, 05/25/2018

Growth & Valuation

Earnings growth (last year)-13.30%
Earnings growth (this year)-16.14%
Earnings growth (next 5 years)+5.33%
Revenue growth (last year)-1.03%
P/E ratio33.4
Price/Sales3.87
Price/Book6.17

Competitors

 Today’s
change
Today’s
% change
AGNAllergan+0.34+0.22%
LLYEli Lilly and Co+0.06+0.07%
ABTAbbott Laboratories-0.14-0.22%
NVONovo Nordisk-0.37-0.77%
Data as of 4:02pm ET, 05/25/2018

Financials

Next reporting dateJuly 26, 2018
EPS forecast (this quarter)$0.43
Annual revenue (last year)$22.7B
Annual profit (last year)$3.0B
Net profit margin13.36%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Pascal Soriot
Executive VP-Operations &
Information Technology
Pam P. Cheng
Corporate headquarters
Cambridge, Cambridgeshire

Forecasts